RU2010148803A - Способы применения кортикотропин-рилизинг фактора для лечения рака - Google Patents

Способы применения кортикотропин-рилизинг фактора для лечения рака Download PDF

Info

Publication number
RU2010148803A
RU2010148803A RU2010148803/15A RU2010148803A RU2010148803A RU 2010148803 A RU2010148803 A RU 2010148803A RU 2010148803/15 A RU2010148803/15 A RU 2010148803/15A RU 2010148803 A RU2010148803 A RU 2010148803A RU 2010148803 A RU2010148803 A RU 2010148803A
Authority
RU
Russia
Prior art keywords
composition
administered
crf
cancer
tumor
Prior art date
Application number
RU2010148803/15A
Other languages
English (en)
Russian (ru)
Inventor
Стефен ЭВАНС-ФРИК (US)
Стефен ЭВАНС-ФРИК
Original Assignee
Ньютрон Роу (Bm)
Ньютрон Роу
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньютрон Роу (Bm), Ньютрон Роу filed Critical Ньютрон Роу (Bm)
Publication of RU2010148803A publication Critical patent/RU2010148803A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2228Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2010148803/15A 2008-04-30 2009-04-30 Способы применения кортикотропин-рилизинг фактора для лечения рака RU2010148803A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4929208P 2008-04-30 2008-04-30
US61/049,292 2008-04-30
US9480608P 2008-09-05 2008-09-05
US61/094,806 2008-09-05

Publications (1)

Publication Number Publication Date
RU2010148803A true RU2010148803A (ru) 2012-06-10

Family

ID=41119761

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010148803/15A RU2010148803A (ru) 2008-04-30 2009-04-30 Способы применения кортикотропин-рилизинг фактора для лечения рака

Country Status (17)

Country Link
US (1) US20100113341A1 (enExample)
EP (1) EP2259793A2 (enExample)
JP (1) JP2011519375A (enExample)
KR (1) KR20110021820A (enExample)
CN (1) CN102036680A (enExample)
AU (1) AU2009241813A1 (enExample)
CA (1) CA2722426A1 (enExample)
CO (1) CO6300959A2 (enExample)
CR (1) CR11762A (enExample)
EC (1) ECSP10010631A (enExample)
IL (1) IL209005A0 (enExample)
MX (1) MX2010011882A (enExample)
NI (1) NI201000185A (enExample)
NZ (1) NZ588877A (enExample)
RU (1) RU2010148803A (enExample)
WO (1) WO2009134396A2 (enExample)
ZA (1) ZA201007729B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives
KR20120124353A (ko) * 2009-06-24 2012-11-13 스티븐 에반스-프레케 암 치료를 위해 코르티코트로핀 방출인자를 사용하는 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852054A (en) * 1956-11-23 1958-09-16 Motley Murat Brunson Container and closure therefor
US4312523A (en) * 1979-10-29 1982-01-26 Paco Packaging Incorporated Label for container having pharmaceutical product therein
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
WO1984001378A1 (en) 1982-09-29 1984-04-12 Karl P Lederis Urotensin peptides
US4528189A (en) * 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5229940A (en) * 1992-01-29 1993-07-20 Conoco Inc. Method of extracting three dimensional information from a grid of two dimensional seismic data
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6319900B1 (en) * 1999-09-21 2001-11-20 The Regents Of The University Of California Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
CN1361180A (zh) * 2000-12-26 2002-07-31 上海博德基因开发有限公司 一种新的多肽——促肾上腺皮质激素释放因子8.8和编码这种多肽的多核苷酸
CN1382700A (zh) * 2001-04-26 2002-12-04 上海博德基因开发有限公司 一种多肽——促肾上腺皮质激素释放因子-12.87和编码这种多肽的多核苷酸
CA2358177A1 (en) * 2001-10-03 2003-04-03 Ted Ramsay Label for pharmaceutical prescriptions
US7919118B2 (en) * 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
KR101235723B1 (ko) * 2004-07-08 2013-02-21 아임스코 리미티드 약제
JP2006036013A (ja) * 2004-07-27 2006-02-09 Yamaha Motor Co Ltd 自動二輪車
US7311205B2 (en) * 2005-01-25 2007-12-25 Target Brands, Inc. Pharmacy bottle system including label
US20100203048A1 (en) * 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer

Also Published As

Publication number Publication date
US20100113341A1 (en) 2010-05-06
CA2722426A1 (en) 2009-11-05
AU2009241813A1 (en) 2009-11-05
IL209005A0 (en) 2011-01-31
CR11762A (es) 2011-04-26
ECSP10010631A (es) 2011-02-28
WO2009134396A2 (en) 2009-11-05
EP2259793A2 (en) 2010-12-15
JP2011519375A (ja) 2011-07-07
NZ588877A (en) 2012-08-31
NI201000185A (es) 2013-04-22
CO6300959A2 (es) 2011-07-21
WO2009134396A3 (en) 2010-04-15
CN102036680A (zh) 2011-04-27
KR20110021820A (ko) 2011-03-04
MX2010011882A (es) 2011-02-25
ZA201007729B (en) 2014-02-26

Similar Documents

Publication Publication Date Title
MX2024000357A (es) Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
UA92907C2 (uk) Похідні тетрагідроіндазолону
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
IN2012DN02826A (enExample)
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
EA201201159A1 (ru) Дейтерированные соединения пирролопиримидина в качестве ингибиторов cdk4/6
RU2008130963A (ru) Лечение метастатического рака молочной железы
MXPA02011913A (es) Triazolopirimidinas sustituidas como agentes anticancer.
WO2006130688A3 (en) Compounds for inhibiting cathepsin activity
WO2001074376A3 (en) Cathepsin inhibitors in cancer treatment
WO2012159085A3 (en) Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
MX2010005629A (es) Preparacion farmaceutica para tratamiento de hiperplasia prostatica benigna.
ATE308515T1 (de) Antizymmodulatoren sowie deren verwendung
TNSN07294A1 (en) Treatment of metastasized tumors
RU2011108486A (ru) ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
RU2005129273A (ru) Противораковый агент, содержащий белок lk8 в качестве активного ингредиента
RU2010148803A (ru) Способы применения кортикотропин-рилизинг фактора для лечения рака
RU2009146882A (ru) Комбинированная противораковая терапия, включающая применение винфлунина и трастуцумаба
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
RU2003118131A (ru) Способ лечения ран
RU2012102259A (ru) Способы применения кортикотропин-рилизинг фактора для лечения рака
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20131002